Straits Times Index
3,193.25 +38.56 (+1.22%) Nikkei
38,044.39 +82.59 (+0.22%) Hang Seng
16,408.22 +156.38 (+0.96%) FTSE 100
7,847.99 +27.63 (+0.35%) Bitcoin USD
61,682.04 -2,693.10 (-4.18%) CMC Crypto 200
885.54 0.00 (0.00%)
Molecular Partners AG (MLLCF)
| Previous close | 3.8000 |
| Open | 3.8000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 3.8000 - 3.8000 |
| 52-week range | 3.4000 - 7.2200 |
| Volume | |
| Avg. volume | 53 |
| Market cap | 124.902M |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.0700 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireMolecular Partners Announces All Board Proposals Approved at the Annual General Meeting
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that all motions proposed by the Board of Directors at the Annual General meeting were approved by the shareholders of the Company by a wide majority. The Molecular Partners shareholders confirmed the approval of the annual review, th
- GlobeNewswire
Molecular Partners Publishes Invitation to Annual General Meeting 2024
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2024. The Annual General Meeting will be held on Wednesday, April 17, 2024, 9.00 CET (doors open at 8.30 CET), at JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland. Invitation to
- GlobeNewswire
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
Research & Development Highlights Presented encouraging initial data from first four dosing cohorts of ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS at the ASH Annual Meeting, reporting an acceptable safety profile and initial anti-tumor activityIntroduced the Switch-DARPin concept and platform at PEGS Europe. In January 2024, introduced the first multispecific Switch-DARPin program, targeting cKIT x CD16a x CD47, as a next-generation conditioning regim
